Singlera Genomics signed a research and distribution agreement with Pure Medical to commercialize its mTitan and mGuard cell‑free DNA methylation assays across select European countries. The deal covers distribution, local research collaborations with hospitals and universities, and engagement with national health systems. Singlera’s platforms profile methylation haplotypes to detect multiple cancers noninvasively. The agreement supports the company’s European market entry and local validation efforts as it advances multi‑cancer early detection and MRD applications.